The FDA has approved the first rapid-acting biosimilar insulin product for glycemic control in people with diabetes. Merilog ...

Intravenous Opdivo, with $2.48 billion in sales, topped the list of precision oncology products in BMS's growth portfolio.

This provides full disease control: intravenous SPEVIGO treats GPP flares, while subcutaneous SPEVIGO prevents them. 5 ...

EMA committee recommends extension of marketing authorisation for Janssen-Cilag’s subcutaneous Rybrevant to treat advanced EGFR-mutated NSCLC: Beerse, Belgium Tuesday, February ...

Janssen-Cilag International NV, a Johnson & Johnson company, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended an ...

Enrollment of Part A completed ahead of schedule and exceeded enrollment target with 123 patients enrolled SAN FRANCISCO and BOSTON, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., ...

The FDA has approved a third biosimilar for tocilizumab, called Avtozma, the second such biosimilar to be available in both intravenous and subcutaneous formulations, according to a press release.

and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced a collaboration with a global pharmaceutical manufacturer on a Phase III clinical ...

The expanded indication is intended to treat a rare ... "We continue to see growth in the overall large volume subcutaneous market with multiple new drugs entering clinical trials and several ...